Northwestern Medicine Regional Medical GroupCadence Occupational Health 245 S Gary Ave STE 200, Bloomingdale, IL 60108 6308948404 (phone), 6308948028 (fax)
Northwestern Medicine Regional Medical GroupCadence Occupational Health 636 Raymond Dr STE 102, Naperville, IL 60563 6309222350 (phone), 6309222070 (fax)
Education:
Medical School Rush Medical College Graduated: 1989
Conditions:
Bronchial Asthma
Languages:
English Spanish
Description:
Dr. Robinson graduated from the Rush Medical College in 1989. He works in Bloomingdale, IL and 1 other location and specializes in Occupational Medicine. Dr. Robinson is affiliated with Central Dupage Hospital and Delnor Community Hospital.
Name / Title
Company / Classification
Phones & Addresses
Dr. Robin Robinson Audiologist
Hearing Solutions Audiology Center Hearing Solutions Audiology Audiologists
Suzanne U. Emerson - Rockville MD Robert H. Purcell - Boyds MD Sergei A. Tsarev - Rockville MD Robin A. Robinson - Dickerson MD
Assignee:
The United States of America as represented by the Secretary of Health and Human Services - Washington DC Novavax, Inc. - Columbia MD
International Classification:
C12N 1551
US Classification:
435 693, 4353201, 530350
Abstract:
The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
An insect cell line capable of growth in serum-free media and secretion of high levels of recombinant proteins, including virus-like particles, upon infection with recombinant baculoviruses, is provided. Methods involving clonal selection processes, serum-weaning and recombinant protein secretion selection are used to create the insect lines of the invention. This cell line supports replication of baculoviruses, serves as host substrate for baculovirus plaque assays, provides a source of insect proteins, acts as a depot for cell transfection to produce recombinant baculoviruses, and express viral recombinant proteins. Extracellular and intracellular viral recombinant proteins and virus-like particles expressed from this cell line are useful as pharmaceutical compositions, vaccines, or diagnostic reagents.
Robin A. Robinson - Dickerson MD, US Peter M. Pushko - Frederick MD, US
Assignee:
Novavax, Inc. - Rockville MD
International Classification:
C12N 7/00 C12N 7/04
US Classification:
4352351, 435 691, 435236
Abstract:
Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.
Robin A. Robinson - Dickerson MD, US Peter M. Pushko - Frederick MD, US
Assignee:
Novavax, Inc. - Rockville MD
International Classification:
C12N 7/04 A61K 39/145
US Classification:
435236, 4352351, 4242041, 4242061, 4242091
Abstract:
Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.
Robin Robinson - Dickerson MD, US Mark Thompson - Morgan Hill CA, US
Assignee:
Novavax, Inc. - Columbia MD
International Classification:
C12N007/02
US Classification:
435/239000
Abstract:
Methods for isolation and purification or recombinant gene products are disclosed. In particular, methods for isolation and purification of extracellular and intracellular viral gene products, including virus-like particles, are disclosed herein.
Optimization Of Gene Sequences Of Virus-Like Particles For Expression In Insect Cells
Codon optimized polynucleotides for optimal expression of recombinant proteins in eukaryotic cells are provided. The codon optimized polynucleotides encode a viral capsid protein that self assembles into a virus-like particle. The virus-like particle is expressed extracellularly and exhibits conformational antigenic epitopes capable of raising neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the gene products of the codon-optimized polynucleotides are also provided.
Optimization Of Gene Sequences Of Chimeric Virus-Like Particles For Expression In Insect Cells
Robin Robinson - Dickerson MD, US Vittoria Cioce - Kinsington MD, US
International Classification:
A61K039/12 C12P021/04 C12N007/00 C12N005/06
US Classification:
424199100, 435456000, 435235100, 435348000
Abstract:
Chimeric virus-like particles that exhibit conformational antigenic epitopes capable of eliciting neutralizing antibodies are disclosed herein. The chimeric virus-like particles of the invention comprise a recombinant viral capsid protein that encapsulates a recombinant viral protein during self-assembly into a chimeric virus-like particle, wherein the chimeric virus-like particle exhibits confirmational antigenic epitopes capable of eliciting neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the chimeric virus-particles are also provided.
Gale SMITH - Gaithersburg MD, US Yingyun Wu - Clarksburg MD, US Michael Massare - Mt. Airy MD, US Peter Pushko - Frederick MD, US Margret Nathan - Montgomery Village MD, US Thomas Kort - Germantown MD, US Robin Robinson - Rockville MD, US
This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
Contra Costa College - Mental Health Counseling, Old Town School of Folk Music - Jazz Vocals 1 and 2, Columbia College - Music theory, Evanston township
Robin Robinson
Education:
Educator, Aviation inst. - Repair, Electric power - Systems
Ernest Morrow Junior High School Calgary Azores 1977-1983, Okotoks High School Okotoks Azores 1982-1984, Foothills Composite High School Okotoks Azores 1983-1985
They have shown very encouraging and promising results, said Robin Robinson, who was the head of Novavaxs vaccine division until 2004, when he left to become the head of BARDAs influenza division, and then its director.
Date: Jul 16, 2020
Category: More news
Source: Google
HHS signs $1.8M contract with Pennsylvania company to develop instant Ebola ...
Fast and inexpensive point-of-care diagnostics will improve our ability to control Ebola virus disease outbreaks, said Robin Robinson, director of HHSs Biomedical Advanced Research and Development Authority.
Date: Jun 12, 2015
Category: Health
Source: Google
BioCryst gets HHS contract for Ebola drug development
BARDA director Robin Robinson, PhD, said in the statement that developing drugs and vaccines against Ebola has been a long-term US goal. "We are making progress quickly to develop product candidates for clinical evaluation and to make products available that protect against this virus," he said.
Date: Mar 31, 2015
Category: Health
Source: Google
HHS Contracts with BioCryst Pharmaceuticals to Develop New Ebola Drug
Developing drugs and vaccines to protect against Ebola has been a long-term goal of the U.S. government, explains BARDA director Robin Robinson, Ph.D. We are making progress quickly to develop product candidates for clinical evaluation and to make products available that protect against this viru
While were encouraged that traditional public health measures and supportive medical care are starting to control the outbreak in West Africa, the need for vaccines and therapeutics remains an urgent priority, said Robin Robinson, director of contract sponsor the Biomedical Advanced Research and
Date: Dec 24, 2014
Category: Health
Source: Google
US looking to boost production of experimental Ebola drug
The US government "is working with partners around the world as quickly as possible to advance the development of multiple vaccine and therapeutic candidates for clinical evaluation and future use in preventing or treating Ebola," BARDA Director Robin Robinson said in a statement.
Date: Oct 18, 2014
Category: Health
Source: Google
Ebola Virus Cure: US Issues 'Task Order' For Ebola Drug ZMapp
anced Development and Manufacturing. The centers were created in 2012, in part, to provide the nation with production surge capacity to meet public health emergencies, said Dr. Robin Robinson, director of the Biomedical Advanced Research and Development Authority. Now, the centers are taking on Ebola. G
Disease Control and Prevention (CDC), Director Dr. Tom Frieden, Dr. Anthony Fauci, director of The National Institute of Allergy and Infectious Diseases, Dr. Robin Robinson, director of the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Service, Dr.